Oarsman Capital’s GSK GSK Stock Holding History

Oarsman Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$336K	Buy	6,406 +97	+2%	+$5.13K	0.04%	177
2026 Q1	$348K	Hold	6,309	–	–	0.04%	166
2025 Q4	$309K	Buy	6,309 +118	+2%	+$5.5K	0.04%	179
2025 Q3	$267K	Sell	6,191 -478	-7%	-$18.7K	0.04%	192
2025 Q2	$256K	Buy	6,669 +115	+2%	+$4.39K	0.04%	205
2025 Q1	$254K	Buy	6,554 +26	+0.4%	+$952	0.05%	196
2024 Q4	$221K	Buy	6,528 +1,450	+29%	+$52.2K	0.04%	214
2024 Q3	$208K	Buy	+5,078	New	+$208K	0.04%	230
2024 Q2	–	Sell	-5,078	Closed	-$218K	–	240
2024 Q1	$218K	Buy	+5,078	New	+$209K	0.05%	217

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Oarsman Capital's GSK Position: Q2 2026 in Review

Oarsman Capital increased its GSK (GSK) stake by 1.5% in Q2 2026, buying an estimated $5.13K and bringing the position to 6,406 shares worth $336K. The position accounts for 0.04% of the portfolio, ranked #177.

Oarsman Capital first reported a position in GSK in Q1 2024 and has held it in 9 quarters since. The position peaked at $348K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Oarsman Capital held 6,406 shares of GSK worth $336K as of Q2 2026.
Oarsman Capital bought 97 GSK shares in Q2 2026, an estimated $5.13K.
GSK made up 0.04% of Oarsman Capital's portfolio in Q2 2026, its #177 holding.
Oarsman Capital first reported a position in GSK in Q1 2024 and has held it in 9 quarters since.
Oarsman Capital's GSK position peaked at $348K in Q1 2026.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Oarsman Capital's 13F filing for Q2 2026, filed 7 Aug 2026.